EYEGATE PHARMACEUTICALS INC
Reported by Raymond James Financial Services Advisors Inc
Reported 0 shares, down 15,000 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
|
This position's reported history falls outside the five-year preview window. A free account unlocks it.
Unlock full history
|
|||||||
Who else reported the position
23 managers reported EYEGATE PHARMACEUTICALS INC for Q4 2018.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL LLC | Added | 17,262,853 | +460,353 | 0.61% | $8,029,000 | 7 qtrs |
| VANGUARD GROUP INC | Added | 131,610 | +16,200 | < 0.01% | $61,000 | 13 qtrs |
| PANAGORA ASSET MANAGEMENT INC | Added | 128,176 | +20,746 | < 0.01% | $60,000 | 2 qtrs |
| ACADIAN ASSET MANAGEMENT LLC | Added | 97,723 | +21,700 | < 0.01% | $46,000 | 4 qtrs |
| Virtu Financial LLC | New | 68,391 | +68,391 | < 0.01% | $32,000 | 1 qtr |
| CITADEL ADVISORS LLC | Added | 48,251 | +12,759 | < 0.01% | $22,000 | 5 qtrs |
| US BANCORP DE | Unchanged | 40,650 | 0 | < 0.01% | $19,000 | 4 qtrs |
| UBS Group AG | New | 26,007 | +26,007 | < 0.01% | $12,000 | 5 qtrs |
| WEDBUSH SECURITIES INC | Unchanged | 20,000 | 0 | < 0.01% | $9,000 | 5 qtrs |
| NORTHERN TRUST CORPORATION | Unchanged | 14,553 | 0 | < 0.01% | $7,000 | 6 qtrs |
Filing details and methodology As reported
- Report period
- December 31, 2018
- Filed
- February 11, 2019
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.